Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study

Table 3 Correlations between variables

	Sex	Age	Disease duration	DAS28-CRP	TJC	SJC	CRP	PtGA (0–100)	HAQ DI	Pain VAS (0–100)	Biological DMARDs	Methotrexate	Steroid	Anxiety	Depression
Sex	1
Age	− 0.10	1
Disease duration	0.16	0.28	1
DAS28-CRP	− 0.01	0.20	0.22	1
TJC	0.03	0.10	0.12	0.81	1
SJC	− 0.01	0.14	0.17	0.67	0.53	1
CRP	− 0.14	0.13	0.08	0.39	0.21	0.27	1
PtGA (0–100)	0.03	0.17	0.19	0.77	0.43	0.35	0.19	1
HAQ-DI	0.06	0.31	0.40	0.56	0.42	0.36	0.24	0.58	1
Pain VAS (0–100)	− 0.06	0.14	0.20	0.67	0.41	0.31	0.15	0.78	0.54	1
Biological DMARDs	0.11	− 0.16	− 0.09	− 0.07	− 0.04	− 0.03	− 0.06	− 0.05	− 0.02	− 0.04	1
Methotrexate	− 0.02	− 0.10	− 0.09	− 0.10	− 0.05	− 0.04	− 0.19	− 0.17	− 0.17	− 0.10	− 0.01	1
Steroids	− 0.08	0.13	0.10	0.22	0.13	0.20	0.23	0.16	0.22	0.14	− 0.02	− 0.17	1
Anxiety	0.03	− 0.01	0.06	0.21	0.13	0.07	0.02	0.32	0.31	0.28	− 0.01	− 0.11	0.07	1
Depression	− 0.04	0.09	0.09	0.22	0.12	0.05	0.03	0.33	0.34	0.24	− 0.01	− 0.12	0.13	0.56	1

DAS28 Disease Activity Score in 28 joints, CRP C-reactive protein, TJC tender joint count; SJC swollen joint count; PtGA patient global assessment, HAQ-DI Health Assessment Questionnaire Disability Index, VAS Visual Analogue Scale, DMARD, disease-modifying anti-rheumatic drugs
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS), Anxiety/Depression: HADS score ≥ 8. VAS range: 0 (no pain) to 100 (maximum pain)

ISSN: 2523-3106